In this context, the purpose of our study is to settle these issues, including how each 10% increment of TILs and high-level TILs in breast cancer and in three tumor phenotypes (luminal, HER2-overexpression and TN) influence the OS and the pathological complete response (pCR) rate. The gene discussed is ERBB2; the disease is breast cancer.